Mambisa (CIGB-669) / Center for Genetic Engineering and Biotechnology - LARVOL DELTA

Validation and Clinical Performance of a Non-Commercial ELISA for SARS-CoV-2 Anti-RBD IgA Antibodies. (PubMed, Anal Biochem) - "This assay was found to be highly accurate and reproducible for the quantification of anti-RBD IgA, met the most stringent acceptance criteria and is fit for purpose. It is currently being used to evaluate the immunogenicity of the Abdala and Mambisa vaccines."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial. (PubMed, Vaccines (Basel)) - "In both phases, anti-RBD IgG titers, inhibition percentages and neutralizing antibody titers increased significantly after the booster dose. Both vaccines were safe and their immunogenicity surpassed the study endpoints."

Journal • P1/2 data • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

Preparing for the Next Pandemic: Increased Expression of Interferon-Stimulated Genes After Local Administration of Nasalferon or HeberNasvac. (PubMed, DNA Cell Biol) - "In most cases, the gene expression induced by HeberNasvac was similar in profile and intensity to the expression induced by Nasalferon and significantly superior to that observed in untreated controls. The immune stimulatory effect of HeberNasvac on ISGs paved the way for its future use as an innate immunity stimulator in elderly persons and immunocompromised subjects or as part of Mambisa, a nasal vaccine to prevent severe acute respiratory syndrome coronavirus 2 infection."

IO biomarker • Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • HLA-DRB1 • ISG15 • ISG20 • STAT1 • STAT3